Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 126

Sort by

Sort Order Select

Journal Articles

Selective targeting of mutated calreticulin by the monoclonal antibody INCA033989 inhibits oncogenic function of MPN

Blood (2024) 144 (22): 2336–2348.

https://doi.org/10.1182/blood.2024024373

Published: 2024

Includes: Supplemental data

Journal Articles

Outcome of Patients with Accelerated and Blast-Phase Myeloproliferative Neoplasms Ineligible for Intensive Chemotherapy or Allogeneic Hematopoietic Cell Transplantation Treated By Azacitidine Alone or in Combination - a FIM Study

Blood (2024) 144 (Supplement 1): 3167.

https://doi.org/10.1182/blood-2024-199055

Published: 2024

Journal Articles

18-Months Follow-up of the Trial of Imatinib after Ponatinib Induction (TIPI) in the Front-Line Treatment of Chronic Phase (CP) Chronic Myeloid Leukemia (CML) Setting

Blood (2024) 144 (Supplement 1): 478.

https://doi.org/10.1182/blood-2024-198903

Published: 2024

Journal Articles

Increased Thromboinflammation Is Associated with High Thrombotic Risk in Patients with Myeloproliferative Neoplasms: A Multicentric Study of 394 Cases By the French Intergroup of Myeloproliferative Neoplasms (FIM)

Blood (2024) 144 (Supplement 1): 3133.

https://doi.org/10.1182/blood-2024-194702

Published: 2024

Journal Articles

Spatial Transcriptomic Profiling of Bone Marrow Vascular Niches Unveils an Endothelial Stress Signature in Myeloproliferative Neoplasms

Jimena Castorena, Christophe Desterke, Barbara Burroni, Lise Willems, Marie-Caroline Le Bousse-Kerdilès, Laurence Legros, Laura Velazquez

Blood (2024) 144 (Supplement 1): 4516.

https://doi.org/10.1182/blood-2024-210924

Published: 2024

Journal Articles

T rial of Imatinib after Ponatinib Induction (TIPI) in the Front-Line Treatment of Chronic Phase (CP) Chronic Myeloid Leukemia (CML) Setting. Report of the First Therapeutic Sequence

Blood (2023) 142 (Supplement 1): 445.

https://doi.org/10.1182/blood-2023-181571

Published: 2023

Journal Articles

Characteristics, Outcomes, Tfr Rates in Young Adults with Chronic Myeloid Leukemia in the Tyrosine Kinase Inhibitor Era: A French Observational Study

Blood (2023) 142 (Supplement 1): 1800.

https://doi.org/10.1182/blood-2023-173132

Published: 2023

Journal Articles

Impact of Cytoreductive Drugs upon Outcomes in a Contemporary Cohort of Adolescent and Young Adults with Essential Thrombocythemia and Polycythemia Vera

Yan Beauverd, Jean-Christophe Ianotto, Kyaw Htin Thaw, Marta Sobas, Parvis Sadjadian, Natalia Curto-Garcia, Lee-Yung Shih, Timothy Devos, Dorota Krochmalczyk, Serena Galli, Maria Bieniaszewska, Ilona Seferynska, Mary Frances McMullin, Anna Armatys, Adrianna Spalek, Joanna Waclaw, Mihnea Tudor Zdrenghea, Laurence Legros, Francois Girodon, Krzysztof Lewandowski, Anna Angona Figueras, Jan Samuelsson, Aitor Abuin Blanco, Pascale Cony-Makhoul, Angela Collins, Chloe James, Rajko Kusec, Marie Lauermannova, Maria Soledad Noya, Malgorzata Skowronek, Lukasz Szukalski, Anna Szmigielska-Kaplon, Marielle Wondergem, Iryna Dudchenko, Joanna Gora-Tybor, Kamel Laribi, Anna Kulikowska De Nalecz, Jean-Loup Demory, Katell Le Du, Sonja Zweegman, Carlos Besses Raebel, Radek C. Skoda, Stephane Giraudier, Martin Griesshammer, Jean-Jacques Kiladjian, Claire N Harrison

Blood (2023) 142 (Supplement 1): 748.

https://doi.org/10.1182/blood-2023-185108

Published: 2023

Journal Articles

Thrombosis with Non-Proliferative Complete Blood Count Indicative of Underlying Myeloproliferative Neoplasm, Sythrom, a Study on Behalf of the FIM Group

Blood (2022) 140 (Supplement 1): 9668–9669.

https://doi.org/10.1182/blood-2022-159928

Published: 2022

Journal Articles

Impact of the COVID-19 Epidemic on Patients with Myeloproliferative Neoplasia: The French Prospective Observational Study Covim

Blood (2022) 140 (Supplement 1): 6847–6849.

https://doi.org/10.1182/blood-2022-156632

Published: 2022

Journal Articles

Onset of Blast Crises in CML Patients in Treatment-Free Remission: Descriptive Analysis of 4 Cases

Stephanie Dulucq, Frédéric Bauduer, Jean-Michel Cayuela, Patrice Chevallier, Pascale Cony-Makhoul, Yannick Le Bris, Laurence Legros, Herve Maisonneuve, Lydia Roy, Francois-Xavier Mahon, Sandrine Hayette, Delphine Rea, Franck E. Nicolini

Blood (2021) 138 (Supplement 1): 2556.

https://doi.org/10.1182/blood-2021-149986

Published: 2021

Journal Articles

Treatment-Free Remissions in Newly Diagnosed CP CML Patients Treated with the Combination of Nilotinib + Pegylated Interferon Alpha 2a Versus Nilotinib Alone in the National Phase III Petals Trial

Blood (2021) 138 (Supplement 1): 2553.

https://doi.org/10.1182/blood-2021-146412

Published: 2021

Journal Articles

Treatment Free Survival (TFS) in Patients (pts) with Chronic Myeloid Leukemia (CML) Carrying Atypical BCR-ABL1 Fusion Transcripts: The French CML Group (Fi-LMC) Experience

Hyacinthe Johnson-Ansah, Aude Charbonnier, Delphine Rea, Gabriel Etienne, Lydia Roy, Laurence Legros, Agnes Guerci Bresler, Anne Bouvier, Emilie Cayssials, Valerie Coiteux, Philippe Rousselot, Stephanie Dulucq, Sandrine Hayette, Francois-Xavier Mahon, Franck E. Nicolini

Blood (2021) 138 (Supplement 1): 3604.

https://doi.org/10.1182/blood-2021-147537

Published: 2021

Journal Articles

Eltrombopag in Chronic Myelomonocytic Leukemia (CMML) with Severe Thrombocytopenia: Final Results of a Multicenter Phase II Study

Blood (2020) 136 (Supplement 1): 15–16.

https://doi.org/10.1182/blood-2020-137469

Published: 2020

Journal Articles

The TKI-Free Duration after a First Discontinuation Attempt That Failed in CP CML Patients Is a Predictive Factor of TKI-Free Remission after a Second Attempt

Laurence Legros, MD PhD, Franck E Nicolini, MDPhD, Gabriel Etienne, MD PhD, Philippe Rousselot, MDPhD, Delphine Rea, MD, Stephane Giraudier, MD PhD, Agnès Guerci, MD PhD, Francoise Huguet, MD, Martine Gardembas, MD, Jean-Christophe Ianotto, MD PhD, Martine Escoffre-Barbe, MD, Valerie Coiteux, MD, Bruno Varet, MD, Stephane Morisset, BioStat, Francois-Xavier Mahon, MD PhD

Blood (2019) 134 (Supplement_1): 28.

https://doi.org/10.1182/blood-2019-123719

Published: 2019

Journal Articles

Prognostication of Molecular Relapses after Dasatinib or Nilotinib Discontinuation in Chronic Myeloid Leukemia (CML): A FI-LMC STOP 2G-TKI Study Update

Delphine Rea, MD, Franck E Nicolini, MDPhD, Michel Tulliez, MD, Philippe Rousselot, MDPhD, Martine Gardembas, MD, Gabriel Etienne, MD PhD, Francois Guilhot, MD, Joelle Guilhot, PhD, Agnès Guerci, MD PhD, Martine Escoffre-Barbe, MD, Laurence Legros, MD PhD, Bruno Villemagne, MD, Gaëlle Guillerm, MD, Marie-Pierre Noel, MD, Valerie Coiteux, MD, Jean-Michel Pignon, MD, Francois-Xavier Mahon, MD PhD

Blood (2019) 134 (Supplement_1): 30.

https://doi.org/10.1182/blood-2019-124408

Published: 2019

Journal Articles

Current Treatments Do Not Improve the Prognosis of Patients with Atypical CML and Unclassified MDS/MPN. a Joint Report from Fi-LMC, FIM, Gfch and GFM

Vaidie Julien, MD, Delphine Rea, MD, Sylvain Thepot, MD, Le Pluart Bruno, MD, Nathalie Gachard, PhD, Stéphanie Struski, MD, Lydia Roy, MD, Cecile Bally, MD, Jo Caers, MD PhD, Franck E Nicolini, MD PhD, Bruno Cassinat, PharmD, PhD, Eric Lippert, MD PhD, Laurence Legros, MD PhD, Raphael Itzykson, MD PhD

Blood (2019) 134 (Supplement_1): 2954.

https://doi.org/10.1182/blood-2019-127254

Published: 2019

Journal Articles

The Combination of Nilotinib + Pegylated IFN Alpha 2a Provides Somewhat Higher Cumulative Incidence Rates of MR4.5 at M36 Versus Nilotinib Alone in Newly Diagnosed CP CML Patients. Updated Results of the Petals Phase III National Study.

Blood (2019) 134 (Supplement_1): 494.

https://doi.org/10.1182/blood-2019-123674

Published: 2019

Journal Articles

Myeloproliferative Neoplasms in Patients below 25 Years Old at Diagnosis: A Retrospective International Cooperative Work

Blood (2018) 132 (Supplement 1): 1759.

https://doi.org/10.1182/blood-2018-99-112374

Published: 2018

Journal Articles

First-Line Second Generation Tyrosine Kinase Inhibitors in Newly Diagnosed Accelerated Phase Chronic Myeloid Leukemia Patients.

Blood (2018) 132 (Supplement 1): 48.

https://doi.org/10.1182/blood-2018-99-113058

Published: 2018

NARROW

Selective targeting of mutated calreticulin by the monoclonal antibody INCA033989 inhibits oncogenic function of MPN

Outcome of Patients with Accelerated and Blast-Phase Myeloproliferative Neoplasms Ineligible for Intensive Chemotherapy or Allogeneic Hematopoietic Cell Transplantation Treated By Azacitidine Alone or in Combination - a FIM Study

18-Months Follow-up of the Trial of Imatinib after Ponatinib Induction (TIPI) in the Front-Line Treatment of Chronic Phase (CP) Chronic Myeloid Leukemia (CML) Setting

Increased Thromboinflammation Is Associated with High Thrombotic Risk in Patients with Myeloproliferative Neoplasms: A Multicentric Study of 394 Cases By the French Intergroup of Myeloproliferative Neoplasms (FIM)

Spatial Transcriptomic Profiling of Bone Marrow Vascular Niches Unveils an Endothelial Stress Signature in Myeloproliferative Neoplasms

T rial of Imatinib after Ponatinib Induction (TIPI) in the Front-Line Treatment of Chronic Phase (CP) Chronic Myeloid Leukemia (CML) Setting. Report of the First Therapeutic Sequence

Characteristics, Outcomes, Tfr Rates in Young Adults with Chronic Myeloid Leukemia in the Tyrosine Kinase Inhibitor Era: A French Observational Study

Impact of Cytoreductive Drugs upon Outcomes in a Contemporary Cohort of Adolescent and Young Adults with Essential Thrombocythemia and Polycythemia Vera

Thrombosis with Non-Proliferative Complete Blood Count Indicative of Underlying Myeloproliferative Neoplasm, Sythrom, a Study on Behalf of the FIM Group

Impact of the COVID-19 Epidemic on Patients with Myeloproliferative Neoplasia: The French Prospective Observational Study Covim

Onset of Blast Crises in CML Patients in Treatment-Free Remission: Descriptive Analysis of 4 Cases

Treatment-Free Remissions in Newly Diagnosed CP CML Patients Treated with the Combination of Nilotinib + Pegylated Interferon Alpha 2a Versus Nilotinib Alone in the National Phase III Petals Trial

Treatment Free Survival (TFS) in Patients (pts) with Chronic Myeloid Leukemia (CML) Carrying Atypical BCR-ABL1 Fusion Transcripts: The French CML Group (Fi-LMC) Experience

Eltrombopag in Chronic Myelomonocytic Leukemia (CMML) with Severe Thrombocytopenia: Final Results of a Multicenter Phase II Study

The TKI-Free Duration after a First Discontinuation Attempt That Failed in CP CML Patients Is a Predictive Factor of TKI-Free Remission after a Second Attempt

Prognostication of Molecular Relapses after Dasatinib or Nilotinib Discontinuation in Chronic Myeloid Leukemia (CML): A FI-LMC STOP 2G-TKI Study Update

Current Treatments Do Not Improve the Prognosis of Patients with Atypical CML and Unclassified MDS/MPN. a Joint Report from Fi-LMC, FIM, Gfch and GFM

The Combination of Nilotinib + Pegylated IFN Alpha 2a Provides Somewhat Higher Cumulative Incidence Rates of MR4.5 at M36 Versus Nilotinib Alone in Newly Diagnosed CP CML Patients. Updated Results of the Petals Phase III National Study.

Myeloproliferative Neoplasms in Patients below 25 Years Old at Diagnosis: A Retrospective International Cooperative Work

First-Line Second Generation Tyrosine Kinase Inhibitors in Newly Diagnosed Accelerated Phase Chronic Myeloid Leukemia Patients.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only